Completed PHASE2 INTERVENTIONAL 2-arm NCT00766038

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury. (Growth-TBI)

A Phase II, Randomized Controlled Trial of Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

Sponsor: Baylor Health Care System

Conditions Traumatic Brain Injury

Interventions Placebo Recombinant human Growth Hormone

Updated 7 times since 2017 Last updated: Nov 13, 2019 Started: Sep 30, 2008 Primary completion: Jun 30, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Traumatic Brain Injury and is currently completed. Baylor Health Care System leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Dec 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor Health Care System
University of Pennsylvania

Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bakersfield, United States
• Dallas, United States